首页工具

Dibutyryl-cGMP sodium

产品编号 T11038 CAS 51116-00-8

别名: Bt2cGMP sodium

Dibutyryl-cGMP sodium (Bt2cGMP sodium) is a cell-permeable cGMP analog. Dibutyryl-cGMP sodium preferentially activates cGMP-dependent protein kinase (PKG). Dibutyryl-cGMP sodium inhibits [3H]-arachidonic acid release in human platelets stimulated by gamma thrombin. Dibutyryl-cGMP sodium can induce peripheral analgesia by activating ATP-sensitive K + channels.

TargetMol的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

Dibutyryl-cGMP sodium Chemical Structure

Dibutyryl-cGMP sodium, CAS 51116-00-8

规格	价格/CNY	货期
2 mg	￥ 1,950	5日内发货
25 mg	￥ 9,700	8-10周
50 mg	￥ 12,600	8-10周
100 mg	￥ 17,500	8-10周

大包装超大折扣，点击咨询

更多批次查询请联系客服

生物活性

化学信息

存储 & 溶解度

参考文献

产品描述	Dibutyryl-cGMP sodium (Bt2cGMP sodium) is a cell-permeable cGMP analog. Dibutyryl-cGMP sodium preferentially activates cGMP-dependent protein kinase (PKG). Dibutyryl-cGMP sodium inhibits [3H]-arachidonic acid release in human platelets stimulated by gamma thrombin. Dibutyryl-cGMP sodium can induce peripheral analgesia by activating ATP-sensitive K + channels.
体外活性	Dibutyryl-cGMP can induce the process of prolongation and branching of astrocytes, which is caused by the rapid, reversible and concentration-dependent redistribution of glial fibrillary acidic protein (GFAP) and actin filaments, while the protein level No significant changes. When the cells were incubated with succinyl-cGMP (100 μM), the formation of stress fibers was prevented, and the cells obtained a star-like morphology in cerebellar astrocytes. In cells treated with dibutyryl-cGMP (100 μM, 2 h), the particle fraction contained almost no RhoA protein. Dibutyryl-cGMP prevents RhoA-membrane binding. Using the scratch model, the size of the wound in cells treated with succinyl-cGMP after the wound was significantly reduced, indicating that dbcGMP accelerated the wound closure.
体内活性	Dibutyryl-cGMP (50-200 μg/paw; subcutaneous injection; male Wistar rats) treatment antagonizes the hyperalgesic effect of PGE2 in a dose-dependent manner. The maximum analgesic effect of DbcGMP was 1 h after the administration and continued for more than 2 h.

别名	Bt2cGMP sodium
分子量	508.38
分子式	C18H24N5NaO9P
CAS No.	51116-00-8

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

计算器

摩尔浓度计算器

稀释计算器

配液计算器

分子量计算器

质量

浓度

容积

分子量

浓度 (起始)

容积 (起始)

浓度 (终)

容积 (终)

溶液体积

质量

配液浓度

参考文献

1. Borán MS, et al. The cyclic GMP-protein kinase G pathway regulates cytoskeleton dynamics and motility in astrocytes. J Neurochem. 2007 Jul;102(1):216-30. 2. Sane DC, et al. Cyclic GMP analogs inhibit gamma thrombin-induced arachidonic acid release in human platelets. Biochem Biophys Res Commun. 1989 Dec 15;165(2):708-14. 3. Soares AC, et al. Dibutyryl-cyclic GMP induces peripheral antinociception via activation of ATP-sensitive K(+) channels in the rat PGE2-induced hyperalgesic paw. Br J Pharmacol. 2001 Sep;134(1):127-31.

剂量换算

对于不同动物的给药剂量换算，您也可以参考 更多...

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算，可以得到母液配置方法和体内配方的制备方法：比如您的给药剂量是10 mg/kg，每只动物体重20 g，给药体积100 μL，一共给药动物10 只，您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法：2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL)，如您需要配置的浓度超过该产品的溶解度，请先与我们联系。

体内配方的制备方法：取 50 μL DMSO 主液，加入 300 μL PEG300，混匀澄清，再加 50 μL Tween 80，混匀澄清，再加 600 μL ddH2O, 混匀澄清。

第一步：请输入动物实验的基本信息

剂量

mg/kg

每只动物体重

给药体积

μL

动物数量

第二步：请输入动物体内配方组成，不同的产品配方组成不同，如有配方需求，可先联系我们提供正确的体内配方。

% DMSO+

% +